Cell augmentation strategies for cardiac stem cell therapies by Cruz-Samperio, Raquel et al.
                          Cruz-Samperio, R., Jordan, M., & Perriman, A. (2021). Cell
augmentation strategies for cardiac stem cell therapies. Stem Cells
Translational Medicine, 10(6), 855-866.
https://doi.org/10.1002/sctm.20-0489
Publisher's PDF, also known as Version of record
License (if available):
CC BY
Link to published version (if available):
10.1002/sctm.20-0489
Link to publication record in Explore Bristol Research
PDF-document
This is the final published version of the article (version of record). It first appeared online via Wiley at
https://stemcellsjournals.onlinelibrary.wiley.com/doi/full/10.1002/sctm.20-0489 . Please refer to any applicable
terms of use of the publisher.
University of Bristol - Explore Bristol Research
General rights
This document is made available in accordance with publisher policies. Please cite only the
published version using the reference above. Full terms of use are available:
http://www.bristol.ac.uk/red/research-policy/pure/user-guides/ebr-terms/

T I S S U E E N G I N E E R I N G AND R E G E N E R A T I V E M ED I C I N E
Cell augmentation strategies for cardiac stem cell therapies
Raquel Cruz-Samperio | Millie Jordan | Adam Perriman
School of Cellular and Molecular Medicine,
University of Bristol, Bristol, UK
Correspondence
Adam Perriman, PhD, School of Cellular and
Molecular Medicine, University of Bristol,
University Walk, Clifton BS8 1TD, UK.
Email: chawp@bristol.ac.uk
Abstract
Myocardial infarction (MI) has been the primary cause of death in developed coun-
tries, resulting in a major psychological and financial burden for society. Current
treatments for acute MI are directed toward rapid restoration of perfusion to limit
damage to the myocardium, rather than promoting tissue regeneration and subse-
quent contractile function recovery. Regenerative cell therapies (CTs), in particular
those using multipotent stem cells (SCs), are in the spotlight for treatment post-MI.
Unfortunately, the efficacy of CTs is somewhat limited by their poor long-term viabil-
ity, homing, and engraftment to the myocardium. In response, a range of novel SC-
based technologies are in development to provide additional cellular modalities,
bringing CTs a step closer to the clinic. In this review, the current landscape of
emerging CTs and their augmentation strategies for the treatment post-MI are dis-
cussed. In doing so, we highlight recent advances in cell membrane reengineering via
genetic modifications, recombinant protein immobilization, and the utilization of soft
biomimetic scaffold interfaces.
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1 | INTRODUCTION
Cardiovascular disease (CVD) accounts for 30% of fatalities globally
and is the leading cause of mortality in middle-to-high-income coun-
tries.1 In 2010, the global economic cost of CVD was USD 863 billon
and it is expected to reach USD 1044 billion by 2030.2 One of the
reasons for this disproportionate economic and societal burden is that
the current treatments for myocardial infarction (MI), such as percuta-
neous coronary intervention (PCI) and coronary artery bypass surgery
(CABG), are costly revascularization procedures which focus on man-
aging the symptoms. PCI and CABG reduce the severity of the injury
and the mortality; however, they fail to address myocardial structure
and functional regeneration, which lead to costly follow-ups, MI
reoccurrence and death.3 The poor prognosis post-MI can be attrib-
uted to limited self-regenerative capacity of cardiac tissue after
ischemic injury as cardiomyocytes (CMs) and cardiac stem cells (CSCs)
die at infarcted site. CSC are then unable to undergo myogenic
differentiation,4,5 and scarring pathways are triggered instead to
replace the dead CMs with viable myofibroblasts. This helps to main-
tain the myocardium structure by stimulating collagen I deposition,
but fails to recapitulate the native tissue tensile strength and contrac-
tile forces that are required for functional left ventricle ejection
pressure, prompting the reoccurrence of heart failure.6 For more
information on the mechanisms and pathways associated with cardiac
repair, the authors refer the reader to the comprehensive review by
Broughton et al.7
Cell therapies (CTs) have emerged as promising regenerative
treatments for range of different diseases, including CVDs (Table 1),
but selecting the right cell type is essential for a successful out-
come.42,43 In early studies, myoblasts and skeletal muscle satellite cells
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were tested as potential CTs to treat MI, due to their capability to
regenerate the muscle integrity of the heart,8 but clinical trials showed
only minor improvements in ejection fraction performance and ven-
tricular tachyarrhythmias.12 These cell phenotypes were superseded
by bone marrow cells (BMCs),13,44 especially bone marrow-derived
mesenchymal stromal cells (MSCs),45 which exhibit desirable proper-
ties for therapy, such as immunomodulatory capacity,46 a tendency to
migrate to inflammation and injury sites, and multipotency.47,48 Early
preclinical studies suggested that MSCs could differentiate into a CM
phenotype,19,20,22,49-51 making them promising candidates for heart
tissue regeneration. However, MSCs transplantation in animal models
post-MI,19,20,22 and in clinical trials, showed only modest levels of
recovery of heart function.12,46,52 Indeed, later studies suggest that
the observed therapeutic benefits result from paracrine effects53,54 or
acute immune responses,21 rather than MSC differentiation and sub-
sequent engraftment. In response, recent preclinical studies have
shown the regenerative potential of the secretome from different
stem and progenitor cells (eg, MSCs, CSCs, embryonic cells, etc.) due
to the cell-specific complex mixture of cytokines, growths factors,
enzymes, and genetic material,55,56 leading to new technologies based
on extracellular vesicles.57,58 Although beyond the scope of the cur-
rent review, the authors direct the reader to the comprehensive
review by Xu et al59 for a detailed assessment of stem and progenitor
TABLE 1 Cell therapies in cardiac therapies and their outcome in different animal models and clinical trials
Cells Small mammal models Swine models Primate models Clinical trials
Myoblasts Aut.,a muscle regeneration8
Aut., enhanced oxygenation,
contractile function recovery9
Al.,b cell survival for 10 days.10









Aut., improved cardiac function,
and higher blood flow and
capillary function after 3 wk15
Aut., improved regional
blood flow and cardiac
function via paracrine
effects16
Aut., improved infarct tissue
perfusion and left
ventricular function17
Aut., decreased infarct size,
improved left ventricular
function18
MSCsd Al., heart regeneration via
differentiation into CMs19





Aut., structural and functional
remodeling22




- Aut. and al., enhanced
ventricular remodeling and
functional capacity24
MSCs-CSCse Aut., decreased infarct size,
improved cardiac function via
paracrine effects25
Aut., scar size reduction26
Al., scar size reduction and
systolic function recovery27
- Aut., undergoing28
iPSCs-CMsf Aut., improved left ventricular
function29







transplanted in cell sheets,
undergoing
hESC-CMsg Al., CMs survived and engrafted
to the heart for weeks35,36
Al., angiogenesis and ECMh
formation37
Al., adequate engraftment38 Al., enhanced
remuscularization39
Al., improvement of left
ventricular function40
Al, transplanted in fibrin
patch, improved systolic
function 41
aAutologous CT (cell source is the patient).
bAllogenic CT (cell source is different than the patient).
cBone marrow cells.
dMesenchymal stromal cells.
eMesenchymal stromal cells combined with cardiac stem cells.
fInduced pluripotent stem cells differentiated into cardiomyocytes.
gHuman embryonic stem cells differentiated into cardiomyocytes.
hExtracellular matrix.
Significance statement
This review outlines the current challenges surrounding the
adoption of stem cell therapies for the treatment of cardio-
vascular disease and the emerging technologies that are in
preclinical development to overcome these hurdles. In doing
so, the authors provide an overview of new approaches to
stem cell membrane reengineering that aim to improve effi-
cacy and reduce off-target effects by improving homing and
retention in the myocardium.
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cell secretomes, Levi et al60 for the scope and limitations of MSCs in
CTs, and to Steinhoff44 for more information on other BMCs studied
in cardiac repair.
MSCs are by no means the only SCs in the spotlight for cardiac
tissue regeneration, as promising preclinical results have also been
achieved using induced pluripotent cells (iPSCs)61 and human embry-
onic stem cell-derived CMs (hESC-CMs).39,40,62 iPSCs have been
shown to be plausible candidates for cardiac therapy in several animal
models.61,63,64 Transplantation of iPSCs predifferentiated into CMs
has been reported to ameliorate ventricular function in rodent
models,29,30 and contractile function in porcine models.31 iPSC-CMs
have also been developed as a potential allogenic CT and tested in
nonhuman primates, displaying electrical integration with the host
heart, leading to improvement of contractile function after 4 weeks
with no significant immune rejection.32 These encouraging preclinical
results supported clinical trials to determine the safety to iPSC-CM
transplantation as cell sheets.33,34
In vivo CT studies to treat cardiac ischemic injury from hypoxia
have postulated a wide range of possible regenerative mechanisms that
are linked to cell type and origin (autologous or allogenic). These include
functional integration with recipient CMs, activating the growth and dif-
ferentiation of endogenous CSCs,65,66 trans-differentiation of
transplanted SCs into new CMs and/or endothelial cells,
metalloprotease-driven cardiac tissue matrix remodeling, as well as via
the recruitment of white blood cells to repair micro-vessels.67,68 Unfor-
tunately, when transplanted via intravenous or intra-arterial infusion,
SCs accumulate in tissue sinks such as the lungs and liver, which
reduces the efficiency of systemic delivery and increases the likelihood
of producing lethal microemboli.69-73 Even when implanted directly into
the region of interest, the number of cells required for therapeutic ben-
efit may be prohibitively high. Indeed, cell tracking experiments per-
formed on a range of cells injected into the infarcted hearts of mice
displaying cell necrosis have shown limited long-term integration, with
only 2% to 10% of cells remaining over the first few days and virtually
none after 3 months.74,75 Such low levels of engraftment and retention
can be rationalized by a number of factors, including the lack of cell
adhesion, turbulent flow, hypoxic microenvironments, and the presence
of inflammatory cytokines.76-78
It is becoming evident that irrespective of their source, therapeu-
tic stems cell need to be recruited/retained near the injury site in
significant numbers and duration to have a positive clinical out-
come.47,79,80 Accordingly, augmenting SCs with soft biocompatible
interfaces that drive homing and engraftment to cardiac tissue could
rapidly accelerate the rate at clinical translation. This review explores
the current and emerging methodologies in cell augmentation technol-
ogy for enhancing the performance of cardiac CTs.
2 | APPROACHES FOR IMPROVING SC
HOMING AND RETENTION
In general, cell homing and adhesion to cardiac tissue can occur via spe-
cific receptor-mediated interactions with the extracellular matrix (ECM)
proteins, or can be initiated via physical/chemical adhesion to cardiac
cells via hydrophobic and electrostatic interactions. It is widely accepted
that SCs target inflammation and injury sites, including infarcted myo-
cardium. Accordingly, many SC membrane reengineering approaches
aim to promote these endogenous processes, but there is a growing
body of literature that describes the development of new targeting
strategies to improve homing efficiency (Figure 1).
2.1 | SDF-1/CXCR4 axis
SCs, such as MSCs, iPSCs, or ESCs, possess a set of cell adhesion
markers (eg, integrins ß1, ß2 [CD18], or VL-4), growth factors (eg,
F IGURE 1 Methods for
augmenting SC to improve homing
and retention in cardiac therapies.
SCs are extracted from the source,
purified, and expanded to achieve the
desired numbers for treatment. Their
cell membrane can be modified to
improve homing to cardiac tissue
genetically, or by using homing
proteins or soft biomaterials. SCs can
be genetically modified prior to the
expansion phase to overexpress
membrane receptors or adhesion
markers. They can also be treated
with proteins that are prone to stick
to cardiac tissue after expansion or
they can be built into scaffolds that
provide them with new functionalities
and properties
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glycoprotein CD34+ or vascular endothelial growth factor [VEGF]) and
chemokine receptors, which play an important role in cell homing to
sites of inflammation.80 In particular, MSCs can come naturally to the
bone marrow niche through binding of the extracellular C-X-C chemo-
kine receptor type 4 (CXCR4) to the stromal cell-derived factor
1 (SDF-1), which is present in the bone marrow.81,82 This interaction
could be readily exploited for cardiac therapies, as SDF-1 expression
is upregulated at the injury site over 48 hours post-MI,80 but unfortu-
nately the MSC expression of CXCR4 is commonly downregulated or
lost during their expansion.83 Several approaches have been reported
to upregulate CXCR4 expression in MSCs during expansion, such as
culturing under hypoxic conditions.84 Moreover, treating MSCs with
growth factors81 such as insulin-like growth factor 1 (IGF-1),85 tumor
necrosis factor α,86 interleukin 1ß,87 interferon γ,88 or pretreating with
chemokines (glycogen synthase kinase 3ß),89 can increase CXCR4
expression. Despite these efforts, CXCR4 expression levels are gener-
ally not sufficient to promote high levels of homing, and endogenous
proteases, such as matrix DPP-4/CD26, degrade this receptor, pro-
moting the loss of MSCs in the myocardium.90
2.2 | Genetically modified SCs
Improving the therapeutic potential of a SC can be achieved geneti-
cally using viral or liposome-based vectors,91 resulting in over-
expression of the protein of interest (Figure 1). Genetic modification
of SCs have focused mainly on increasing paracrine factor production,
inducing differentiation into CMs or improving retention or integra-
tion with the heart in cardiovascular diseases.91,92 Chen et al and
Zhang et al parallelly showed that retrovirus- or adenovirus-induced
overexpression of CXCR4 in MSCs resulted in a respective decrease
in anterior wall thinning and left ventricular remodeling,93 and an
increase in angiogenesis and myogenesis94 when transplanted in rats
post-MI. Similarly, overexpression of SDF-1, the CXCR4 natural coun-
terpart, in transplanted MSCs has shown increased recruitment of
endogenous SCs, leading to a 20% decrease in fibrotic area and 20%
increase in ejection fraction compared to saline in rats.95 However,
rather than targeting homing, most studies on MSC genetic modifica-
tion have focused on improving their therapeutic potential by either
augmenting their paracrine factor production96-101 or by facilitating
their differentiation into CMs.102
Some of the first examples in the literature displayed enhanced
MSC survival after implantation in ischemic rat myocardium by retro-
virally inducing overexpression of pro-survival factors, such as Akt96
or Bcl-2,97 leading to reduced inflammation and up to 90% recovery
of myocardial volume and cardiac performance for the former (Akt)
and 32% increased survival of the implanted MSCs, causing a 17%
reduction of the infarct size for the latter (Bcl-2). Other approaches
induced overexpression of angiogenesis factors in MSCs, such as
VEGF98,99 or GATA-4.100 VEGF-expressing MSCs have been reported
to promote angiogenesis and improve the infarct size after a month
by 10% in rats98 and 30% in sheep99 post-MI, whilst GATA-4 trig-
gered antiapoptotic pathways when overexpressed in MSCs,
displaying a threefold increase in ejection fraction and fractional
shortening compared to unmodified MSCs in mice after MI.100
Directly overexpressing the growth and transcription factor regulator,
thioredoxin-1, in MSCs improved proliferation by 20%, and most
importantly, the production of VEGF, heme oxygenase-1 (HO-1) and
CXCR4 after 4 days from implantation in rats, resulting in improved
contractility and ejection fraction after 60 days.101 Finally, MSC dif-
ferentiation into CMs has been achieved via overexpressing the
cardiomyogenic transcription factor myocardin before transplanting
the cells in mice post-MI. MSCs overexpressing myocardin displayed
enhanced engraftment with the heart and recovered left ventricular
function after 15 days from treatment.102
Overall, genetic modification is a versatile and exciting approach
to enhance MSCs therapeutic performance and retention in the heart;
however, the cost associated with reprogramming can be prohibitively
high. Moreover, the modifications are permanent and the use of viral
vectors is subject to insertional oncogenesis.47
2.3 | Protein-based membrane modifications
Direct protein-based membrane modification strategies provide tran-
sient display of the targeting construct and present a number of
potential benefits over generic approaches for improved cell homing.
These include, a reduction in risk arising from oncogenesis in the ther-
apeutic cells, minimal impact on the cell manufacturing process as the
modification step can be readily integrated into an existing therapeu-
tic pipeline, the display number per cell can be systematically varied to
reduce the risks associated with patient-specific expression levels,
and protein production is scalable and can be produced using good
manufacturing practice procedures.103,104
An excellent example of direct protein-based membrane modifi-
cation was demonstrated by Won et al, who displayed recombinantly
produced CXCR4 on MSC membranes using lipid-PEG vesicles
(Figure 2A).105 They demonstrated that CXCR4 was only present in
the MSCs membrane after delivery by confocal microscopy studies
without affecting the viability of MSCs and showed up to a twofold
improvement in their migration toward SDF-1 following a concentra-
tion gradient in vitro. This noninvasive approach allowed facile
reengineering of MSC membranes within 2 minutes, which is espe-
cially relevant for autologous therapies, considering that genetic modi-
fication methods can take several weeks, missing the ideal therapeutic
window for treating the infarcted myocardium.
Besides the SDF-1/CXCR4 axis, homing to ECM adhesion pro-
teins overexpressed in inflammation sites, such as selectin and fibro-
nectin, has also been investigated.106-108 There are several avenues to
achieve this, one being the covalent conjugation of MSCs to
E-selectin binding peptides in a two-step process (Figure 2B). Here,
the free amine groups in MSC membrane proteins are functionalized
with NHS-PEG2-maleimide, and then ligated to free thiols of the
E-selectin binding peptide. This resulted in successful SC adhesion
and rolling on immobilized E-selecting under up to 0.5 dyn/cm2 sheer
stress in vitro, without affecting cell viability, proliferation, or
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multipotency.106 However, direct covalent modifications of free
amines on cell surfaces lacks target membrane protein specificity and
could give rise to downstream toxicity or immunogenicity. Moreover,
plasma membrane proteins are involved in many different signaling
cascades, and their modification could potentially affect MSCs fate
and subsequent therapeutic performance. Accordingly, other
approaches aim to only modify the plasma membrane non-covalently.
One approach involves decorating a human antibody (IgG1) with
P-selectin glycoprotein ligand-1 (Figure 2C). The modified IgG1 binds
to the MSCs cell membrane, conferring the MSCs enhanced adhesion
and rolling to P-selectin and E-selectin 1 and 2 dyn/cm2 shear stress,
respectively. The therapeutic applicability of this method was demon-
strated by showing MSC retention to human umbilical vein endothe-
lial cells (HUVECs) under static (up to 10 dyn/cm2) and hydrodynamic
shear (up to 4 dyn/cm2).107 Similarly, a recent study by Wu et al dem-
onstrated that antibodies could be used to direct MSCs to cardiac
tissue via membrane biotinylation and binding to a streptavidin-
conjugated antibody specific to inflamed endothelium.109 This
approach conferred MSCs with a twofold increase in retention to an
ischemic myocardium without diminishing MSC cell viability in a
mouse model. Moreover, the authors also demonstrated target
specificity by subjecting antibody-modified and nonmodified MSCs to
HUVECs coated with the antibody epitope under physiologically rele-
vant wall stress shear, obtaining the same trends observed in the
mouse model.
Recently, Perriman et al developed a noncovalent methodology
to rapidly display proteins and enzymes on the plasma membrane of
mesenchymal SCs.108,110,111 These designer proteins comprise super-
cationic protein-polymer surfactant plasma membrane binding
domains that spontaneously assemble at the cell surface (Figure 2D).
When the team applied the methodology in the field of targeted
cardiac CTs, they demonstrated that the inherent cardiac homing
properties of the oral bacterial Streptococcus gordonii could be trans-
ferred to hMSCs through the rational design of a membrane active
bacterial adhesin protein chimera. Here, the fibronectin binding
domain of the bacterial adhesin CshA was expressed as a fusion with
supercharged green fluorescent protein and the resulting modified
hMSCs showed a twofold increase in number of cells in myocardium
after either intravenous or intracardiac injection in a murine model,
without a commensurate increase in the lungs.
Another excellent example of direct plasma membrane modifica-
tion involves the application of biotinylated lipid vesicles, which has
been used to coat MSCs with biotin for subsequent functionalization
with biotin-binding moieties (Figure 2E). Here, biotin's high binding
affinity for streptavidin was exploited to attach streptavidin-
conjugated P-selectin homing ligands to MSCs, enhancing MSC rolling
interactions to P-selectin under up to 0.75 dyn/cm2 dynamic flow
conditions.103 The best P-selectin interaction was obtained at
0.5 dyn/cm2 shear stress, where 80% of modified MSCs showed
interaction vs only 32% nonmodified MSCs, but this difference
became rapidly smaller at higher forces. Reengineering MSCs mem-
brane with biotinylated lipid vesicles is an appealing, versatile method
to modify cell membranes as any protein conjugated to streptavidin
can be implemented and the authors demonstrated that the modified
vesicles had no negative impact on MSC viability, adhesion to
polystyrene surfaces or MSC multipotency.
The nongenetic approaches to cell membrane modification dis-
cussed above highlight the breadth of approaches for reengineering
F IGURE 2 Protein-based reengineering SC membranes to improve homing in cardiac therapies. A, Vesicle-mediated CXCR4 delivery to insert
ligand in the membrane of SCs. B, Chemical functionalization of free amines to covalently attach E-selectin binding peptide (ESBP) to SC
membrane. C, Conjugating antibodies to P-selectin binding domain (PSBD) to deliver ligand to membrane through antibody-epitope
interactions. D, Surfactant-coated supercharged proteins conjugated to fibronectin binding domain (Fn-BD) strongly interact with SC
membrane. E, Vesicles decorated with biotin merge with the cell membrane of SCs to allow further functionalization of SCs with proteins, such as
PSBD, conjugated to streptavidin
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SCs membranes, and for a more in-depth look at the field, the authors
direct the reader to the comprehensive reviews by Lee et al112 and
Armstrong et al.113 What is becoming clear, however, is that despite
the fact that the approaches lead to an increase in target affinity,
there is still a lack of compelling preclinical data to support clinical
translation. Even so, cell membrane reengineering using proteins is an
exciting methodology to augment SCs and next-generation new pro-
tein ligation tools are emerging,114,115 which will allow rapid
bioorthogonal functionalization of SCs to instill a range of new prop-
erties and cellular functions.
3 | SOFT BIOMATERIALS FOR SC
DELIVERY
Despite not being strictly a direct cell membrane modification
approach, soft biomaterials can provide an ECM-like environment to
the transplanted SCss, which can have a major impact on cell adhesion
at an infarcted site, cell survival and retention in the myocardium, and
hence the overall efficiency of the treatment. Accordingly, the applica-
tion of injectable hydrogels, cell patches and cell sheets, and their
respective performances are discussed below (Figure 3).
3.1 | Hydrogels as transplant matrices
The incorporation of injectable hydrogels in CTs has drawn much
attention in the last decade, as they provide a biocompatible three-
dimensional matrix to the transplanted cells (Figure 3A) and form the
basis for the majority of bioinks used in 3D bioprinting.116,117
Preclinical cardiac CT studies have utilized a range of biologically
derived hydrogels from mammalian sources, such as collagen, and
polysaccharides like hyaluronic acid (HA), as well as other nature-
derived examples, which include chitosan (from seafood industry
waste) or alginate (from seaweed), which are biodegradable and have
similar mechanical properties to the infarcted tissue.118 Several key
examples have shown that acellular injectable hydrogels of different
compositions are safe for cardiac implantation in murine
models.119-121 These studies also showed an increase in endogenous
BMCs homing to the heart after injection of HA hydrogels modified
with recombinantly expressed SDF-1119,120 or with collagen I hydro-
gels embedded with histone deacetylase 7 peptide.121 In both cases,
enhanced angiogenesis and recovery of left ventricular function were
observed, and infarct size decreased up to fourfold in comparison with
the control models. Recent clinical trials have reported that injecting
patients suffering from heart failure with acellular alginate hydrogels
is safe and increased the rate of recovery when combined with
standard treatments.122
The scope of using hydrogels in cardiac therapies is not limited to
acellular transplantations, as many efforts report successful delivery
of embedded cells in hydrogels to infarcted tissue in animal models
(Figure 3A')123-126 and clinical trials.127 Hydrogels not only can be
transplanted as matrices, but can also be directly injected and have
been shown to protect the transplanted cells from the mechanical
shear of injection128 and increase the cell number and retention at the
targeted tissue.129 Early clinical trials in patients with ischemic injury
involved injecting autologous BMCs embedded in a collagen I hydro-
gel, however, despite proving to be safe for the patients, no major
improvement in heart function was observed.127 New efforts have
focused on improving the efficacy of these CTs by the addition of
F IGURE 3 Biomaterials can provide SCs with an ECM-like microenvironment to promote adhesion and retention in the myocardium and,
ultimately, to enhance SC therapeutic outcome. A, Acellular hydrogels modified with specific factors (eg, SDF-1) recruit endogenous SCs after
transplantation. A', Cellular hydrogels protect the implanted cells from mechanical stress from the injection. B, Cardiac patches offer the best
short-term protection and retention, but they are more rigid than the other options and usually fail to couple electromechanically with the
heart. C, Cell sheets can contain monolayers of single cell types or coculture of different types to contribute to different processes involved in
cardiac repair
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signaling ligands (eg, Notch ligand delta-1)123 and peptides derived
from growth factors (eg, insulin-like growth factor 1, angiopoietin-
1)124,125 to enhance the survival of the transplanted cells, and by
improving the mechanical properties of the gel.126,130 A recent study
has reported successful implementation of hESC-CMs in a collagen
hydrogel modified with recombinant Notch ligand delta-1 in rats.123
The Notch signaling ligand doubled both the proliferation rate of the
implanted hESC-CMs and the graft size compared to the controls,
even when the cells were transplanted in subtherapeutic numbers.
Another key study has shown that embedding the C-terminal
domain peptide of IGF-1 in chitosan hydrogels containing MSCs
improved cell survival by threefold in mice by protecting the
transplanted cells from oxidative stress, resulting in enhanced angio-
genesis by over 60%, 30% reduction in collagen deposition, and gen-
eral improvement of cardiac function.124 Improving the hydrogel
delivery to reduce mechanical stress during injection could also have a
beneficial effect on the survival of the transplanted cells. Endothelial
progenitor cells (EPCs) have been reported to enhance vasculogenesis
by a fourfold in rats when implanted in HA hydrogels, which exhibit
enhanced shear-thinning properties and hence improved delivery via
injection.126,130 A deeper understanding on how to rationally design
hydrogels to improve the efficacy of transplanted CTs is still required
before they can be effectively translated to the clinic, but advances in
this field are to be expected after the initial clinical trials have
endorsed their safety. One of the main limitations of these
approaches remains the immune rejection of the transplanted graft.
Nevertheless, a recent exciting report of Kim et al. describes how this
may be overcome by encapsulating regulatory T-cells (Tregs)
cocultured with murine pancreatic islets in alginate-gelatin
methacryloyl hydrogels for the treatment of type I diabetes
mellitus.131 This approach should be explored in cardiac repair grafts
when considering that Tregs have been shown to be safe in clinical
trials and are currently supplemented during liver transplants to
suppress immune rejection.131 For more information on Tregs and
their mechanism of suppression graft immune rejection, authors refer
the reader to the review by Romano et al.133
3.2 | Cardiac patches
Cardiac patches have emerged as a potential solution for the poor
retention and survival of transplanted cells in the heart (Figure 3B).
Here, SCs or SC-derived CMs, are grown in vitro and then adhered to
a scaffold that suits the size of the injury, and that has a matrix that
allows oxygen diffusion and resistance to contractile forces. Once the
desired cell confluency is achieved on the patch, it is surgically
implanted. The main limitation of this exciting approach is that is it dif-
ficult to integrate electromechanically and immunologically within the
heart and the transplanted cells display low long-term survival in ani-
mal models.134 For example, initial phase I clinical trials have reported
short- and medium-term safety of transplanting hESCs in fibrin-based
patches in six patients, but no information on the hESC survival rate
or the patch electromechanical coupling was recorded.41 Phase I
clinical trials to determine the safety of hESC collagen patches have
been completed in November 2020, but the outcome is yet to be
published.
In an effort to overcome some of the limitations of cardiac pat-
ches, novel next-generation designs are emerging, which include
cellulose nanofibers MSC patches to enhance neovascularization of
infarcted myocardium in rats,135 porous polymeric polyvinyl alcohol
microneedles to ameliorate nutrient flow between the CSC patch and
the myocardium in rats and swine post-MI,136 and overexpression of
cell proliferation factor, hepatocyte growth factor, in the transplanted
MSCs to maintain constant cell numbers in the cardiac patch despite
the hypoxic environment in porcine post-MI models.137 Moreover,
efforts are being made to reduce the size of the constructs to alleviate
the need for invasive surgeries, for example, the development micro-
scale hESC-CMs patches via intramyocardial injection in rats, which
also improved their electromechanical coupling to the host heart.138
Another limitation of this technology is that cardiac patches need
to be freshly prepared to ensure cell viability and functionality of the
transplanted cells, and thus, they are unavoidably transplanted few
days after the infarction event, compromising the efficacy of the
treatment. A recent paper by Huang et al., presented the first example
of a promising acellular, off-the shelf cardiac patch that can be easily
prepared by mixing porcine decellularized myocardial ECM and a
solution of synthetic CSCs factors embedded in biodegradable
microparticles.139 This patch reduced scarring and promoted angio-
myogenesis by 40% and left ventricular ejection fraction by 15% in
rats and was shown to be safe in pigs, even after been cryopreserved
for 4 weeks prior to the study. Further studies are needed to
determine its safety and efficacy in patients, but it is a promising
avenue for cardiac patch development.
3.3 | Cell sheet technologies
Cell sheet technology is an attractive alternative to cardiac patches, as
the resulting structures exhibit high cell concentration and uniformity,
confer more resistance to degradation upon implantation, and only
rely on the formation of tight cell-to-cell junctions and ECM protein
secretion, rather than an artificial scaffold (Figure 3C).140 Cell sheets
are prepared by culturing monolayers of cells on temperature-
responsive substrates, which become nonadherent at low
temperatures,141 and provides the opportunity to produce cellular
multilayers through direct manipulation (up to three layers) or sequen-
tial assembly on a hydrogel-coated plunger (up to five layers).142 Once
the cell sheet is formed, it detaches from the substrate via a tempera-
ture change, which allows for efficient and effective surgical imple-
mentation. The approach has been used to transplant a wide range of
cells to infarcted myocardium, including autologous myoblasts,143
autologous skeletal cells,144 allogenic cardiac progenitor cells145 and
allogenic iPSC-CM.146 Overall, the approach has been shown to
enhance cardiac regeneration in several animal models when com-
pared with the direct injection of cell suspensions, possibly due to
retention of higher cell numbers on the heart and the formation of
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tight cellular junctions within the sheets. There are currently allogenic
iPSC-CM cell sheets undergoing clinical trials to determine their safety
and efficacy on patients with chronic ischemic cardiopathy combined
with bypass graft surgery.33
Cell sheet technology also provides a clear pathway for the
development of cellular structures with multiple cell types, which can
contribute collectively during cardiac regeneration. For example, fibro-
blasts are essential for the maintenance of the ECM environment,
endothelial cells for the formation of new capillaries, smooth muscle
cells for neovascularization and neurons for autonomic control to the
heart.147 Early examples are the transplantation of fibroblast sheets
cocultured with EPCs148 and EPC sheets cocultured with CMs149 in
rats post-MI, respectively. Both studies reported a 10- and 2-fold
increase in vessel formation respectively, linked to the presence of
EPCs in the graft, compared to the monoculture counterparts, but also
reduced the formation of fibrotic tissue when compared to EPC grafts,
suggesting that the fibroblasts and CM key players in the tissue regen-
eration. Similarly to EPC cocultures, a recent example has combined
iPSC-CM sheets with the vascular-rich pedicle omentum flap to
enhance the endurance of the graft through improvements the blood
supply in a mini-pig MI model.146 iPSC-CM cell sheets improved the
cardiac function after a month in the presence and absence of the
omentum; however, the graft combined with the omentum was
reported to augment the capillary density by twofold, upregulate para-
crine factors (eg, VEGF, SDF-1) and promote CM maturation after
3 months, compared to the iPSC-CM sheet implantation only. More
studies to determine the safety and therapeutic potential of cell
sheets are needed, but cocultures of different cell types seem to be
the most promising avenue.
4 | CONCLUSION AND FUTURE
PERSPECTIVES
CTs are now starting to emerge as a credible alternative to current MI
treatments as they address cardiac repair via activation of endogenous
SCs (CSCs, MSCs, etc.) or via engraftment into the heart. However,
many of the challenges that reduce their efficacy still remain, such as
poor long-term cell survival, limited homing, tumor formation, and lack
of retention in the infarcted myocardium. Nevertheless, the fast-
growing development of new technologies to reengineer the membrane
of SCs or provide a supporting biocompatible matrix may alleviate these
limitations. It is clear that genetic approaches are extremely exciting, as
they can be implemented through reliable protocols that are easy to
track in the preclinical phase (eg, co-expression of fluorescent proteins),
and have a low risk of triggering unwanted immune responses. How-
ever, the risk of mutation-derived oncogenesis is still a concern, which
paves the way for transient non-genetic SC modification approaches.
Another potential limitation is that current reprogramming methodolo-
gies are not temporally compatible with autologous CTs, as the expan-
sion phase is lengthened by several weeks, missing the ideal
therapeutic window after MI. Similarly, cardiac patches and cell sheets
also require extended culture periods. This cell number challenge could
be overcome with the development of an allogenic CT, giving rise to a
readily accessible off-the-shelf treatment, which could be subjected to
high quality control processes.24,150
With respect to the developments within the biomaterial scaffold
space, although they offer an effective solution to myocardium cell
retention and cell number, the transplant process is generally more
invasive, and challenges with effective electromechanical integration
still remain. Shear thinning injectable hydrogels have great potential, as
they are generally less invasive, offer protection to the transplanted
cells from mechanical stress, and provide a rudimentary micro-ECM
that can be systematically tuned for cell signaling. It is also worth
highlighting efforts on transplantation of acellular hydrogels and
cardiac patches that attract endogenous stem/progenitor cells and pro-
vide them with a scaffold to promote long-term survival. Moreover,
these scaffolds could be modified or implemented in combination with
molecules that activate the recruited cells (eg, statins or TGF-β/Wnt
signaling molecules) and amplify their therapeutic potential. In conclu-
sion, it is likely that no single approach to SC membrane reengineering
will provide the “magic bullet” for cardiac CTs, and that the next gener-
ation of therapies will likely utilize combinations of these technologies
to fully harness the therapeutic potential of transplanted SCs.
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